At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 222 enrolled
Drug / intervention
Vibegron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
In Brief
A Phase 2 clinical trial evaluating Vibegron and Placebo for Irritable Bowel Syndrome. Completed, enrolled 222 participants across 41 sites.
Detailed Summary
This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedJan 2019
Primary CompletionSep 2020
Study CompletionOct 2020
TodayJul 2026
First PostedJan 16, 2019
Enrollment StartDec 31, 2018
Primary CompletionSep 25, 2020
Study CompletionOct 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.5 years ago
Interventions
Vibegrondrug
oral administration
Placebodrug
oral administration